This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

SHINGRIX Logo

Prescribing Information

Coding for SHINGRIX

Here you’ll find vaccine product codes and some common administration codes associated with immunization using SHINGRIX. Select another vaccine here.

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

Description: SHINGRIX is supplied as 2 components: a single-dose vial of lyophilized glycoprotein E antigen component (powder) and a single-dose vial of adjuvant suspension component (liquid).1

Dosage: 0.5 mL1

Coding for SHINGRIX

CPT Code2

90750

ICD-10-CM Code3*

Z23

MVX Code4

SKB

CVX Code5

187

NDCs† (Supplied as package of 1 dose)

Outer Carton

NDC 58160-819-12

Lyophilized antigen vial (powder)

NDC 58160-828-01

Adjuvant suspension vial (liquid)

NDC 58160-829-01

NDCs† (Supplied as package of 10 doses)

Outer carton

NDC 58160-823-11

10 vials of lyophilized antigen (powder)

NDC 58160-828-03

10 vials of adjuvant suspension (liquid)

NDC 58160-829-03
Tip

Tip

To promote accuracy, always consult the most current Prescribing Information or product packaging when documenting NDCs.

SHINGRIX CPT Code – Immunization Administration Codes6‡

90471:

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), one vaccine (single or combination vaccine/toxoid)

90472:

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), each additional vaccine (single or combination vaccine/toxoid)
(List separately in addition to code for primary procedure)

Diagnosis Codes

Z23 is the ICD-10-CM code used when reporting an encounter for immunization for all vaccines given within the encounter. In some instances, additional ICD-10-CM coding may be needed. 

See all code types

GSK Codes Summary Sheet

Get a PDF of the most current CPT, CVX, MVX, and NDC codes for GSK vaccines.

Download

Questions?

Find answers to frequently asked questions, along with additional resources, to guide you to the information you need.

Get help

  •   *ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.3
  •   †Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.7 For example, when reporting NDC 58160-823-11 to TRICARE, it becomes NDC 58160-0823-11.
  •    ‡Adapted from the American Medical Association, CPT 2023 Professional Edition, Current Procedural Terminology (CPT), 2024.

References:

  1. Prescribing Information for SHINGRIX.
  2. Centers for Disease Control and Prevention. Immunization and Information System (IIS). https://www2.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cpt Accessed August 5, 2024.
  3. Centers for Medicare and Medicaid Services. 2023 ICD-10-CM official guidelines for coding and reporting. https://www.cms.gov/files/document/fy-2023-icd-10-cm-coding-guidelines-updated-01/11/2023.pdf Accessed May 20, 2024.
  4. Centers for Disease Control and Prevention. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx Accessed May 20, 2024.
  5. Centers for Disease Control and Prevention. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=cvx Accessed May 20, 2024.
  6. American Medical Association. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listing) long descriptors. hhttps://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf Accessed May 20, 2024.
  7. Humana Military. Office injectable guidelines, national drug code (NDC) pricing and filing tips. https://www.humanamilitary.com/provider/claims/injectables#nucleustabs-ee21c6fea3-item-098209c56a-tab Accessed May 20, 2024.

Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.

Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles):

  • in adults aged 50 years and older.
  • in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • In a postmarketing observational study, an increased risk of Guillain-Barré syndrome was observed during the 42 days following vaccination with SHINGRIX
  • Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • Solicited local adverse reactions reported in individuals aged 50 years and older were pain (78%), redness (38%), and swelling (26%)
  • Solicited general adverse reactions reported in individuals aged 50 years and older were myalgia (45%), fatigue (45%), headache (38%), shivering (27%), fever (21%), and gastrointestinal symptoms (17%)
  • Solicited local adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were pain (88% and 83%), redness (30% and 35%), and swelling (21% and 18%)
  • Solicited general adverse reactions reported in autologous hematopoietic stem cell transplant recipients (aged 18 to 49 and ≥50 years of age) were fatigue (64% and 54%), myalgia (58% and 52%), headache (44% and 30%), gastrointestinal symptoms (21% and 28%), shivering (31% and 25%), and fever (28% and 18%)
  • The data are insufficient to establish if there is vaccine-associated risk with SHINGRIX in pregnant women
  • It is not known whether SHINGRIX is excreted in human milk. Data are not available to assess the effects of SHINGRIX on the breastfed infant or on milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

Please see full Prescribing Information for SHINGRIX.